NICE approves Lenvima for differentiated thyroid cancer
NICE has issued its final appraisal decision recommending reimbursement of Lenvima for the treatment of progressive, locally advanced or metastatic, differentiated thyroid carcinoma...
List view / Grid view
NICE has issued its final appraisal decision recommending reimbursement of Lenvima for the treatment of progressive, locally advanced or metastatic, differentiated thyroid carcinoma...
A kinase inhibitor called cabozantinib could be a viable therapy option for patients with metastatic, radioactive iodine-resistant thyroid cancer...